/ Print /

IN THE PIPELINE

Adopting a multidiagnostic method for characterising the anterior segmentA multidiagnostic device is able to provide consistent measurements of refraction and ocular aberrations in healthy eyes. The consistency of refractive measurements is not dependent on the magnitude of the refractive error, with the same precision ability for moderate to high myopia and for hyperopia.
Long-term observation of SMILE gives better myopia prognosisLong-term observation of SMILE reveals high stability at various degrees of correction of myopia. This allows surgeons who apply this method of treatment to give patients a long-term prognosis.
Low-dose atropine for myopia in children: two years of experienceChildren in Tel Aviv have been treated with nightly atropine drops, significantly slowing the progression of myopia.
Applying micropulse transscleral cyclophotocoagulation for early-stage glaucoma Micropulse transscleral cyclophotocoagulation utilises a different delivery modality than its predecessor, continuous-wave laser cycloablation, to produce a biological reaction without the lethal effects caused by thermal buildup.
Yet another new revolution in ocular surface imagingDuring the past two decades, an incredible number of imaging technologies have been developed for eye diseases, both for diagnosis and follow-up.
Activists: drugmakers, distributors liable for opioids abuseSoon after President Donald Trump announced declared the opioid abuse crisis a “public health emergency," shareholder activist groups said they aim to hold drug manufacturers and distributors liable for their part in the crisis.
FDA okays unique injectable for type 2 diabeticsFDA approved a new once-weekly, single-dose autoinjector device to improve glycemic control in adults with type 2 diabetes.
Intravitreal brimonidine holds promise for slowing GA growthBrimonidine Drug Delivery System (Brimo DDS) in an intravitreally administered, sustained-release implant (Allergan) shows promise as a treatment for geographic atrophy (GA), secondary to age-related macular degeneration in a phase IIa clinical trial.
Novel brolucizumab fosters as real-world alternative for nAMDTopline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
New diabetes drug set to rival TrulicityIf it is approved by FDA, an investigational drug to improve glycemic control in patients with type 2 diabetes will likely be a strong competitor to Eli Lilly’s dulaglutide (Trulicity).